Sanara Medtech Inc. (SMTI) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Company: Sanara Medtech Inc.
Reporting Period: Quarter ended September 30, 2024 (Q3 2024)
Segments: The Company reorganized into two reportable segments effective Q2 2024: Sanara Surgical (soft tissue repair and bone fusion products) and Tissue Health Plus (THP) (value-based wound care services). All revenue in Q3 2024 was generated by the Sanara Surgical segment; THP has not yet commercially launched.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Net Revenue | $21.67 million | $16.02 million | $60.37 million | $47.30 million |
| Gross Profit | $19.68 million | $14.27 million | $54.48 million | $41.24 million |
| Gross Margin | 91% | 89% | 90% | 87% |
| Net Loss | $(2.88) million | $(1.09) million | $(8.21) million | $(4.18) million |
| Net Loss Per Share (Basic/Diluted) | $(0.34) | $(0.13) | $(0.96) | $(0.49) |
| Cash and Equivalents | $16.28 million | $5.15 million (Dec 31, 2023) | N/A | N/A |
| Total Debt (Long-term) | $30.08 million | $9.11 million (Dec 31, 2023) | N/A | N/A |
| Segment EBITDA (Total) | $0.84 million | $0.27 million | $1.75 million | $(0.32) million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 35% year-over-year in Q3 and 28% for the nine-month period, driven by increased sales of soft tissue repair products (CellerateRX Surgical) and geographic expansion.
- Margin Expansion: Gross margins improved to 91% in Q3 2024 from 89% in Q3 2023, attributed to higher sales volume and the elimination of royalties on CellerateRX Surgical following the 2023 Applied Asset Purchase.
- Increased Expenses: Operating expenses rose significantly due to the buildout of the THP platform infrastructure, higher sales commissions, and executive separation costs ($1.0 million in 9M 2024).
- Debt Restructuring: The Company secured a new $55.0 million CRG Term Loan facility in April 2024, borrowing $30.5 million to date. This replaced the prior Cadence Term Loan, resulting in higher interest expense ($0.93 million in Q3 2024 vs. $0.19 million in Q3 2023).
- Investments: The Company invested $5.0 million in ChemoMouthpiece, LLC (CMp) in September 2024 and advanced a $1.08 million convertible loan receivable.
Guidance, Outlook, and Risks
- THP Launch: The Tissue Health Plus (THP) value-based wound care program is targeted for commercial launch in mid-2025. Management estimates continued investment of $5.0 million to $10.0 million through the launch period.
- Debt Covenants: The CRG Term Loan requires the Company to maintain minimum annual revenue thresholds: $60.0 million for 2024, $75.0 million for 2025, increasing to $105.0 million by 2028. It also requires a minimum liquidity of $3.0 million.
- Temporary Sales Boost: Q4 2024 saw a temporary sales increase for BIASURGE due to IV fluid shortages caused by Hurricane Helene; management expects this to normalize.
- Risks: Key risks include the ability to meet revenue covenants, the success of the THP commercialization, and the impact of high interest rates on cash flow. The Company is a smaller reporting company and is not required to provide quantitative market risk disclosures.
Investor Verification Checklist
- Covenant Compliance: Verify if the Company will meet the $60.0 million annual revenue covenant for 2024 given current run rates.
- THP Capital Needs: Assess the $5M-$10M funding requirement for the THP launch and the Company's plan to secure financial partners.
- Debt Service: Review the impact of the 13.25% interest rate on the CRG Term Loan (including 5.25% PIK interest) on future cash flows.
- Earnout Liabilities: Monitor the fair value adjustments of earnout liabilities related to the Precision Healing merger and Applied Asset Purchase.
- Related Party Transactions: Review ongoing royalty and service agreements with related parties (e.g., Rochal, Catalyst) and their impact on margins.